Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 44HER2-positive Breast Cancer 8Carcinoma, Non-Small-Cell Lung 5Breast Diseases 3Brain Neoplasms 3Advanced Breast Cancer 3Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Salivary Gland Neoplasms 1Rare Tumour 1Rare Tumor 1Pathologic Complete Response 1Non Small Cell Lung 1Neoplasm Metastasis 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1Metastatic Breast Cancer in the Brain 1Lung Neoplasms 1HER2-positive Metastatic Breast Cancer 1HER2-positive Early Breast Cancer 1HER2+ Early or Locally Advanced Breast Cancer 1HER2 Positive Metastatic Breast Cancer 1HER2 Positive Breast Cancer 1HER2 Insertion Mutation Positive Advanced NSCLC 1Estrogen Receptor-positive Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Digestive System Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Breast Cancer Invasive 1

Interventions

pembrolizumab 31Gemcitabine 26Nivolumab 20atezolizumab 16Cisplatin 15avelumab 14Carboplatin 12Docetaxel 10enfortumab vedotin 8Magnetic Resonance Spectroscopy 8durvalumab 7Specimen Handling 7Paclitaxel 7Ipilimumab 6toripalimab 5pemigatinib 5cabozantinib 5vinflunine 4sacituzumab govitecan 4Taxes 4Pemetrexed 4tislelizumab 3cabazitaxel 3Standard of Care 3Mitomycin 3Injections 3Everolimus 3Albumin-Bound Paclitaxel 3sapanisertib 2olaparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Transitional Cell × pyrotinib × Clear all
NCT05318339 2022-04-08

A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma

ChineseAMS

Phase 2 Unknown
30 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡